Columbia Technology Ventures

sRAGE for neointimal hyperplasia prevention

This technology is a formulation that uses soluble receptors for advanced glycation end products (sRAGE) to prevent neointimal hyperplasia and atherosclerosis.

Unmet Need: A targeted therapy for preventing accelerated atherosclerosis in diabetes

Diabetic patients often experience cardiovascular complications, including accelerated atherosclerosis. Current methods of counteracting this include using antibodies and other immune system modulators to inhibit neointimal hyperplasia. These treatments often yield suboptimal modifications to immune function, as they are not specific to the root cause of diabetic restenosis.

The Technology: A specific intervention for diabetic neointimal hyperplasia using sRAGE

This technology uses sRAGE to compete against the activity of RAGE and specifically prevent the accelerated formation of atherosclerotic tissue in diabetes. By targeting the RAGE pathway, this therapy minimizes off-target effects and can be administered locally through a stent or other device. As inhibitors of RAGE have been shown to prevent unwanted tissue growth after blood vessel injury, this technology may improve neointimal health and decrease the probably of developing atherosclerosis after cardiovascular procedures.

This technology has been shown to suppress neointimal formation in a rat model of diabetes.

Applications:

  • Inhibition of unwanted tissue growth in blood vessels after injury
  • Neointimal hyperplasia prevention
  • Prevention of recurring stenosis in diabetic patients
  • Reduction of complications after angioplasty and stenting

Advantages:

  • Specific to the root causes of diabetic hyperplasia
  • Non-toxic
  • Fewer side effects than immune system modulators
  • Effective for preventing neointimal formation

Lead Inventor:

Ann Marie Schmidt, M.D.

Patent Information:

Patent Status

Related Publications:

Tech Ventures Reference: